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Abstract
Heparin-binding protein (HBP) is an inducer of vascular endothelial leakage in severe infections. Fluid accumulation into alveoli is a general
ﬁnding in acute respiratory distress syndrome (ARDS). Severe acute respiratory failure with ARDS is a complication of inﬂuenza A(H1N1)
infection. Accordingly, we studied the HBP levels in critically ill patients with infection of inﬂuenza A(H1N1).Critically ill patients in four
intensive care units (ICUs) with polymerase chain reaction (PCR) conﬁrmed infection of inﬂuenza A(H1N1) were prospectively evaluated.
We collected clinical data and blood samples at ICU admission and on day 2. Twenty-nine patients participated in the study. Compared with
normal plasma levels, the HBP concentrations were highly elevated at baseline and at day 2: 98 ng/mL (62–183 ng/mL) and 93 ng/mL (62–
271 ng/mL) (p 0.876), respectively. HBP concentrations were correlated with the lowest ratio of partial pressure of oxygen in arterial blood
to fraction of inspired oxygen (PF ratio) during the ICU stay (rho = 0.321, p <0.05). In patients with and without invasive mechanical
ventilation, the baseline HBP levels were 152 ng/mL (72–237 ng/mL) and 83 ng/mL (58–108 ng/mL) (p 0.088), respectively. The respective
values at day 2 were 223 ng/mL (89–415 ng/mL) and 81 ng/mL (55–97 ng/mL) (p <0.05). The patients with septic shock/severe sepsis
(compared with those without) did not have statistically signiﬁcant differences in HBP concentrations at baseline or day 2. HBP
concentrations are markedly elevated in all critically ill patients with inﬂuenza A(H1N1) infection. The increase in HBP concentrations seems
to be associated with more pronounced respiratory dysfunction.
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Introduction
Heparin-binding protein (HBP) is an immunomodulatory
protein secreted by activated neutrophils [1]. The action of
HBP on capillary endothelium is responsible for the leakage of
ﬂuid into the extracellular space and is responsible for the
neutrophil-evoked permeability changes [2]. HBP is a prom-
ising new biomarker for the evolution of septic shock and
increased levels have been shown 12 h prior to development
of septic shock [3]. However, HBP does not seem to
discriminate between patients according to the aetiology of
shock (i.e. between non-septic shock and septic shock) [4].
Increased concentrations of HBP have been described in both
groups regardless of aetiology of shock compared with
patients with local infection only [4].
Inﬂuenza A(H1N1)-infected patients most often have a mild
clinical course of the disease. Of hospitalized inﬂuenza A
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(H1N1) patients, 6–31% require treatment in intensive care
units [5–7]. In ICUs the inﬂuenza A(H1N1) patients often
present with pneumonia, severe hypoxaemic acute respiratory
failure and acute respiratory distress syndrome (ARDS) [6,8].
Increased alveolar permeability is a major component of the
pathogenesis of the development of ARDS. This increased
alveolar permeability may be due to injury to alveolar epithelial
cells or the capillary endothelium. Either way the leakage of
ﬂuid into the interstitium and alveolar space leads to impaired
respiratory function. The accumulation of ﬂuid will, in turn,
enhance the migration of inﬂammatory cells into the alveolar
space and further enhance the inﬂammatory reaction [9].
In previous studies, no increase in plasma HBP levels has
been detected in patients with local bacterial infections,
including pneumonias [4]. Our aim is to study the concentra-
tions in patients with severe viral infection and inﬂuenza A
(H1N1), and its possible associations with respiratory function.
Methods
This is a prospective substudy of the previously published
H1N1 study [10]. In the main study, all patients with ICU
admission and high suspicion of pandemic inﬂuenza A(H1N1)
infection were screened. High suspicion of inﬂuenza A(H1N1)
infection was deﬁned as oseltamivir treatment and/or real-time
reverse transcription polymerase chain reaction (PCR) sample
being taken. Only patients with a positive PCR test result for
inﬂuenza A (H1N1) were included in the main study popula-
tion. All patients in the main study were eligible for the
substudy, which was performed in four ICUs. The study period
was during the Finnish H1N1 outbreak from 11 October 2009
to 31 December 2009.
The ethics committee of Helsinki University Central
Hospital approved the study. The informed consent was
waived for data collection from patient charts in the main
study. For the substudy, with collection of blood samples, a
signed informed consent was obtained from the patient or
next-of-kin.
Data collection
The Finnish Intensive Care Consortium quality database
Intensium Ltd (Kuopio, Finland) provided routine benchmark-
ing data and study-speciﬁc internet-based case report forms
and data warehouse services.
The collected clinical data are described in detail in the main
study [10]. With routine benchmarking data we acquired age,
gender, Simpliﬁed Acute Physiology Score (SAPS) II, Sequential
Organ Failure Assessment (SOFA) score components, and
hospital and ICU admission/discharge times, as well as ICU and
hospital mortality. The clinical study data consisted of: patient
demographics, details of mechanical ventilation, information on
severe sepsis or septic shock, the number of quadrants in
chest X-rays with inﬁltration, presence of acute respiratory
distress syndrome (ARDS) [11] and adjunctive therapy for
acute respiratory failure and other organ failures.
The plasma samples were collected immediately after ICU
admission (baseline) and on the second day of ICU treatment.
The samples were centrifuged in local laboratories and stored
at 20°C. The samples were transferred and stored at 70°C
until analysis. The plasma HBP was determined by enzyme-
linked immunosorbent assay as described earlier [1]. The
detection limit of the method was 0.25 ng/mL and CV variance
was <5%.
Statistical analysis
The data are presented as medians and interquartile range
(IQR) or absolute numbers (range), as appropriate. The
normality of distribution of continuous parameters was tested
with the Kolmogorov-Smirnov one-sample test. In the case of
non-normal distribution, the parameters were transformed to
natural logarithm before analysis. The differences between
study populations were analysed by the Mann–Whitney U-test
or Wilcoxon signed rank test, as appropriate. The differences
in HBP concentrations between groups were calculated by
one-way analysis of variance. In SPSS the missing data are
deleted list-wise. The intraclass (ICC) correlation coefﬁcient
was used to examine the correlation between HBP levels, the
lowest PF ratio, the highest SOFA score, white blood cell
(WBC) count and C-reactive protein (CRP). We assessed HBP
concentrations above 15 ng/mL as signiﬁcantly elevated, a cut-
off value that has been shown to be the best predictive cut-off
value for severe sepsis [3]. p <0.05 is considered statistically
signiﬁcant. We used PASW Statistics 19.0 (SPSS Inc., Chicago,
IL, USA) for statistical analysis.
Results
The main study population consisted of 132 patients with high
suspicion of inﬂuenza A(H1N1) infection and a positive PCR
test. Of these patients, 29 were included in the substudy (28
patients with baseline samples and 25 patients with day 2
samples). The patient characteristics are presented in Table 1.
The overall plasma HBP concentrations were similar at both
sampling times: 98 ng/mL (62–183 ng/mL) at baseline samples
compared with 93 ng/mL (62–271 ng/mL) (p 0.876) at day 2.
The HBP concentrations were above 15 ng/mL [3] in all
patients, both at baseline and at day 2. The lowest concen-
tration of HBP was 32 ng/mL in a non-septic patient. No
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patient had severe leucopenia; the WBC count in the lowest
tertile was 2.7–4.7 x 109/L. The HBP/WBC ratio at baseline
was 15 (9.0–25.9), the smallest value being 6.2. HBP concen-
trations were correlated with the WBC count at baseline
(rho = 0.444, p <0.01) (Fig. 1) and the lowest PF ratio during
the ICU stay (rho = 0.321, p <0.05). No correlation could
be shown between the HBP concentrations with the highest
SOFA score during the ICU stay (rho = 0.255, p 0.08) or
HBP concentration and C-reactive protein (CRP)
(rho = 0.266, p 0.179) (Fig. 1).
When comparing patients with and without invasive
mechanical ventilation during ICU stay, a difference in HBP
concentrations was observed on day 2. Baseline concentra-
tions were 152 ng/mL (72–237 ng/mL) vs. 83 ng/mL (58–
108 ng/mL) (p 0.088) at day 2 and 223 ng/mL (89–415 ng/mL)
vs. 81 ng/mL (55–97 ng/mL) at day 2 (p <0.01), respectively
(Fig. 2, Table 2). In patients with the lowest PF ratio
<100 mmHg, HBP concentrations were signiﬁcantly higher
compared with those with the lowest PF ratio  100 mmHg
at day 2 (p <0.05), and also signiﬁcantly higher in patients who
received corticosteroid treatment during the ICU stay com-
pared with those who did not receive corticosteroid treat-
ment (p <0.05) (Fig. 3, Table 2). No signiﬁcant difference was
found between patients with the lowest PF ratio <100 mmHg
and those with lowest PF ratio  100 mmHg or between
those treated with corticosteroid and those not treated with
corticosteroid at baseline (Fig. 3, Table 2). The patients with
septic shock or severe sepsis during their ICU stay had high
concentrations of HBP at baseline and day 2, but the difference
was not statistically signiﬁcant when compared with those
without septic shock or severe sepsis (Fig. 3, Table 2). The
patients with ARDS and those without did not have signiﬁcant
differences in their HBP concentrations at baseline or day 2
(Table 2).
TABLE 1. Study patients in main study and HBP substudy.
Data are presented as median [interquartile range] or
number (percentage)
All patients in main study
(n = 132)
p value
HBP
substudy
(n = 29)
Patients
not in
substudy
(n = 103)
Age, years 47 [39–56] 49 [29–56] 0.891
Gender, male 20 (69%) 65 (63%) 0.562
Body mass index >35 kg/m2a 11 (38%) 22 (21%) 0.105
Smoker 13 (45%) 33 (32%) 0.125
Chronic obstructive
pulmonary disease
1 (3.4%) 8 (7.8%) 0.411
SAPS II points 24 [20–32] 29 [21–37] 0.093
SOFA score 3 [2–7] 5 [2–8] 0.174
At admission
CRP (mg/L) 73 [33–163] 101 [39–175] 0.533
White blood cell count (x109) 6.4 [4.8–10.1] 7.3 [4.9–9.8] 0.683
Septic shock/severe sepsis 7 (24%) 29 (28%) 0.067
Number of inﬁltrated
quadrants on X-ray
4 [2–4] 2 [1–4] 0.053
PF ratio, mmHg 135 [101–261] 140 [104–240] 0.841
During intensive care unit stay
Ventilatory support
No/non-invasive ventilation 16 (55%) 49 (48%) –
Invasive mechanical ventilation 13 (45%) 54 (52%) 0.196
Length of mechanical
ventilation, days
2 [0–10] 0.9 [0–8] 0.510
The lowest PF ratio, mmHg 100 [76–134] 111 [75–184] 0.366
ARDS 19 (66%) 39 (37.9%) 0.013
Steroid treatment 17 (59%) 55 (53.4%) 0.619
Bacterial culture positive (blood) 1 (3.4%) 8 (7.8%) 0.470
Bacterial culture positive (any) 8 (28%) 30 (29.1%) 0.900
Renal replacement therapy 1 (3.4%) 10 (9.7%) 0.283
Maximum SOFA score 7 [3–9] 6 [4–11] 0.664
Intensive care unit length
of stay, days
4.6 [2.2–9.9] 3.9 [1.9–12.1] 0.910
Hospital length of stay, days 12 [7–16] 15 [7–28] 0.108
Intensive care unit mortality 1 (3.4%) 4 (3.9%) 0.914
Hospital mortality 1 (3.4%) 9 (8.7%) 0.343
SAPS, simpliﬁed acute physiology score; SOFA, sequential organ failure assess-
ment; CRP, C-reactive protein; PF, ratio of partial pressure of oxygen in arterial
blood to fraction of inspired oxygen; ARDS, acute respiratory distress syndrome.
aBody mass index not calculated for children under 14 years of age, n = 9.
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FIG. 1. Heparin binding protein (HBP) concentrations (ng/mL) at
admission correlated with WBC (white blood cell) count (x109) at
admission (rho = 0.444, p <0.01) but not with CRP (C-reactive
protein, g/L) at admission (rho = 0.266, p 0.179).
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Discussion
In this prospective observational study we found that plasma
HBP concentrations were markedly elevated in critically ill
patients with PCR-conﬁrmed inﬂuenza A(H1N1) infection
compared with normal plasma levels at baseline. Furthermore,
we demonstrated a signiﬁcant difference in concentrations at
day 2 between patients with invasive mechanical ventilation
and those without, patients with the lowest PF ratio
<100 mmHg and those above 100 mmHg, and patients
receiving corticosteroid treatment and those without corti-
costeroids. This implies higher HBP concentrations in patients
with more severe pulmonary damage. In patients with septic
shock or severe sepsis the difference was not statistically
signiﬁcant. The observed high HBP concentrations were
correlated with WBC count at baseline and the lowest PF
ratio, but not with the highest SOFA score or CRP levels.
In previous studies, a cut-off value of 15 ng/mL has been
shown to have the best predictive value for the development
of septic shock [3,12]. In healthy controls, the median (range)
HBP levels have been 6.3 (5.0–9.7) ng/mL and in febrile
patients with local infections (urinary tract infection, pneumo-
nia and gastroenteritis) the median (range) concentrations
have been 7.1 (4.4–10.2) ng/mL, 7.0 (5.4–10.3) ng/mL and 5.8
(3.7–8.8) ng/mL, respectively [4].In our study population, all
patients had HBP concentrations well above the proposed cut-
off value for septic shock both at baseline and at day 2.
Inﬂuenza A(H1N1) infection in our study population presented
as lower respiratory tract infection. HBP has been identiﬁed as
a possible biomarker for septic shock, and to our knowledge,
no studies in patients with upper respiratory tract infection
have been conducted. In the study by Chew et al. the
concentrations of HBP were similar in both healthy controls
and febrile patients with pneumonia without systemic inﬂam-
matory response syndrome (SIRS) [4].
In earlier studies, the HBP/WBC ratio has been calculated
for the correction of possibly low HBP levels due to low
neutrophil count [3,12]. With the use of the HBP/WBC ratio
in addition to the HBP concentration cut-off value of 15 ng/
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FIG. 2. Upper panel: HBP concentrations (ng/mL) in patients with
and without invasive mechanical ventilation at baseline (p 0.088) and
day 2 (p <0.01). Lower panel: HBP concentrations in tertiles of
patients divided according to admission PF ratio at baseline and day 2
(p ns).
TABLE 2. Plasma concentrations of HBP (heparin binding
protein) in patient subgroups. Data are presented as median
[interquartile range]
All patients with blood sampling
(n = 29)
HBP
concentration
baseline
HBP
concentration
day 2
Invasive mechanical ventilation
during ICU stay
152 ng/mL
[72–237 ng/mL]
223 ng/mL
[89–415 ng/mL]a
No invasive mechanical ventilation
during ICU stay
83 ng/mL
[58–108 ng/mL]
81 ng/mL
[55–97 ng/mL]
The lowest PF ratio < 100 mmHg
during ICU stay
108 ng/mL
[59–226 ng/mL]
188 ng/mL
[86–389 ng/mL] b
The lowest PF ratio  100 mmHg
during ICU stay
87 ng/mL
[64–118 ng/mL]
81 ng/mL
[55–112 ng/mL]
ARDS during ICU stay 106 ng/mL
[67–232 ng/mL]
124 ng/mL
[71–364 ng/mL]
No ARDS during ICU stay 72 ng/mL
[48–119 ng/mL]
81 ng/mL
[57–97 ng/mL]
Admission CRP < 100 83 ng/mL
[51–127 ng/mL]
84 ng/mL
[54–108 ng/mL]
Admission CRP  100 130 ng/mL
[72–296 ng/mL]
128 ng/mL
[84–326 ng/mL]
Corticosteroid treatment during
ICU stay
128 ng/mL
[70–219 ng/mL]
124 ng/mL
[84–409 ng/mL]b
No corticosteroid treatment during
ICU stay
75 ng/mL
[58–108 ng/mL]
74 ng/mL
[54–113 ng/mL]
Septic shock or severe sepsis during
ICU stay
183 ng/mL
[108–247 ng/mL]
223 ng/mL
[54–332 ng/mL]
No septic shock or severe sepsis during
ICU stay
83 ng/mL
[58–118 ng/mL]
90 ng/mL
[64–134 ng/mL]
ICU, intensive care unit; PF, ratio of partial pressure of oxygen in arterial blood to
fraction of inspired oxygen; ARDS, acute respiratory distress syndrome.
ap <0.01, comparisons of HBP concentrations at day 2 between the subgroups.
bp <0.05, comparisons of HBP concentrations at day 2 between the subgroups.
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mL, additional shock patients have been found [12]. In our
H1N1-positive patients the HBP/WBC ratio was above 6 in all
of our patients although there were still some patients with
low WBC count; the lowest tertile of patients had their WBC
count between 2.7 and 4.7 9 109/L.
Inﬂuenza A(H1N1) patients rapidly develop severe pro-
gressive respiratory failure, which is often associated with
failure of other organs [13]. In the early phases of ARDS,
there is protein-rich ﬂuid accumulation and disruption of
both the alveolar epithelium and the pulmonary capillary
endothelium. This inﬂammatory process is mediated by
activated neutrophils and macrophages [9]. Heparin-binding
protein may contribute to the neutrophil-associated vascular
leakage in acute inﬂammation [2]. High concentrations of
HBP in our patients imply that H1N1 infection results in
signiﬁcant release of HBP in humans. Moreover, association
of HBP levels with the severity of respiratory dysfunction
suggests a role of the neutrophil-derived protein in the
development of lung tissue damage and respiratory failure in
inﬂuenza A(H1N1) infections. Recently, in a mouse model of
H1N1 infection, it was shown that mice depleted of
macrophages had severe pulmonary pathology: excessive
neutrophil inﬁltration, alveolar damage and increased viral
load. These changes later progressed to ARDS-like pathology,
diffuse alveolar damage, pulmonary oedema, haemorrhage
and hypoxemia. In contrast, neutrophil-depleted mice had
only mild pathological changes in their lungs, pointing to a
critical role of neutrophils in H1N1 infections [14]. The
authors provided evidence for the formation of neutrophil
extracellular traps (NETs), which might contribute to the
pulmonary damage.
The role of neutrophils in pulmonary infections with
inﬂuenza A has not been clearly deﬁned. In severe infections,
pulmonary damage is driven by both neutrophils and
macrophages [9]. In animal studies, a decreased number of
circulating leucocytes with an increased proportion of
polymorphonuclear cells has been associated with increased
intensity of pulmonary damage [15]. On the other hand,
mice depleted of neutrophils have presented with exacer-
bated pulmonary inﬂammation, oedema and respiratory
dysfunction [16]. In a comparison of macrophage-depleted
mice with neutrophil-depleted mice, pulmonary damage was
more pronounced in macrophage-depleted mice when
infected with inﬂuenza A(H1N1) [14]. In human patients
who died of inﬂuenza A(H1N1) infection, intensive pulmo-
nary inﬁltration of neutrophils was documented in patients
presenting with necrotizing bronchiolitis, but only mild or
moderate inﬁltration in patients without necrotizing bron-
chiolitis [17].
Previously, increased HBP levels have been associated with
the progression of septic shock and severe sepsis in hospi-
talized patients [3,12]. In a recently published study, HBP
levels were elevated not only in patients with septic shock but
also in patients with circulatory shock due to other reasons
when compared with healthy control patients or with patients
with local infection only [4]. In this study we found no
statistically signiﬁcant differences in HBP concentrations
between patients with septic shock/severe sepsis and other
inﬂuenza A(H1N1) patients. Septic shock/severe sepsis was,
however, present in only three of the 29 patients at ICU
admission and four additional patients were later diagnosed as
having septic shock/severe sepsis during their ICU stay. The
concentrations of HBP in septic patients were markedly
elevated in both samples. Additionally, even the lowest
concentration of HBP in the non-septic patients was 32 ng/
mL at baseline (i.e. higher than the previously reported cut-off
value for septic shock).
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FIG. 3. Heparin binding protein concentrations (ng/mL) at baseline
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signiﬁcant at baseline; p <0.05 at day 2) and with and without severe
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Our study has some limitations. First, the main study was
designed to describe the intensive care treatment and
outcome in Finnish ICUs during the outbreak of an inﬂuenza
A(H1N1) pandemic. Due to the observational nature of the
main study a waiver of consent was approved. As an informed
consent was mandatory for blood sampling in the substudy,
there was substantial loss of potential study subjects and the
substudy was performed in four ICUs only. However, no
signiﬁcant differences in demographic data between the patient
populations were present and thus we consider our results as
representative. The small sample size affects the interpretation
of the observed HBP concentrations in patient subgroups.
Quite large differences in the concentrations of HBP in patient
subgroups (Table 2) (e.g. septic shock/severe sepsis vs. non-
septic patients) were not statistically signiﬁcant. We anticipate
that type II error may be present (i.e. we could not detect a
difference in HBP concentrations in patient subgroups even
though it is there). Finally, recurrent samples during the ICU
stay may have provided more information regarding the
association of HBP and respiratory dysfunction. However, to
the best of our knowledge this study is the ﬁrst to provide
important new information regarding HBP levels in H1N1-
infected critically ill patients.
Conclusions
Heparin-binding protein concentrations were markedly ele-
vated in all critically ill patients with inﬂuenza A(H1N1)
infection even in the presence of a low white cell count. The
increase in HBP concentrations seems to be associated with
more pronounced respiratory dysfunction.
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